カテゴリー： 世界, 医療/バイオ, LP Information

世界の糖尿病用経口薬市場予測 2023年-2029年

【英語タイトル】Global Oral Medicines for Diabetes Market Growth 2023-2029

LP Informationが出版した調査資料（LP23DC03882）・商品コード：LP23DC03882
・発行会社（調査会社）：LP Information
・発行日：2023年11月
・ページ数：111
・レポート言語：英語
・レポート形式：PDF
・納品方法：Eメール（受注後2-3営業日）
・調査対象地域：グローバル、日本、アメリカ、ヨーロッパ、アジア、中国など
・産業分野：医薬品＆医療
◆販売価格オプション（消費税別）
Single User（1名様閲覧用）USD3,660 ⇒換算￥549,000見積依頼/購入/質問フォーム
Multi User（20名様閲覧用）USD5,490 ⇒換算￥823,500見積依頼/購入/質問フォーム
Corporate User（閲覧人数制限なし）USD7,320 ⇒換算￥1,098,000見積依頼/購入/質問フォーム
※販売価格オプションの説明
※お支払金額：換算金額（日本円）＋消費税
※納期：即日〜2営業日（3日以上かかる場合は別途表記又はご連絡）
※お支払方法：納品日＋5日以内に請求書を発行・送付（請求書発行日より2ヶ月以内に銀行振込、振込先：三菱UFJ銀行/H&Iグローバルリサーチ株式会社、支払期限と方法は調整可能）
❖ レポートの概要 ❖

LPインフォメーションの最新刊調査レポート「世界の糖尿病用経口薬市場」は、過去の販売実績から2022年の世界の糖尿病用経口薬の総販売量を検討し、2023年から2029年の予測される糖尿病用経口薬の販売量を地域別・市場分野別に包括的に分析しています。本調査レポートでは、地域別、市場分野別、サブセクター別の糖尿病用経口薬の市場規模を掲載し、XXX百万米ドル規模の世界の糖尿病用経口薬市場の詳細な分析を提供します。本インサイトレポートは、世界の糖尿病用経口薬業界を包括的に分析し、製品セグメント、企業情報、売上、市場シェア、最新動向、M&A活動に関する主要トレンドを明らかにしています。
また、本レポートでは、加速する世界の糖尿病用経口薬市場における各社の独自のポジションをより深く理解するために、糖尿病用経口薬製品ポートフォリオ、能力、市場参入戦略、市場でのポジション、海外展開に焦点を当て、主要なグローバル企業の戦略を分析しています。

世界の糖尿病用経口薬市場規模は、2022年のXXX百万米ドルから2029年にはXXX百万米ドルに成長すると予測され、2023年から2029年までの年平均成長率は000%と予測されます。糖尿病用経口薬の米国市場は、2022年のXXX百万米ドルから2029年にはXXX百万米ドルに増加し、2023年から2029年までのCAGRは000％と予測されています。糖尿病用経口薬の中国市場は、2023年から2029年までの年平均000％成長率で、2022年のXXX百万米ドルから2029年にはXXX百万米ドルに増加すると推定されます。糖尿病用経口薬のヨーロッパ市場は、2023年から2029年にかけて年平均000％成長率で、2022年のXXX百万米ドルから2029年にはXXX百万米ドルに増加すると推定されています。

糖尿病用経口薬の世界主要メーカーとしては、Bayer、 Merck、 Novartis、 Huadong Medicine、 Sanofi、 Novo Nordisk、 Servier、 Takeda Pharmaceutical、 Luye Pharmaceutical、 Taiji Group、 CR Double-Crane、 AstraZeneca、 Boehringer Ingelheim、 Qilu Pharmaceutical、 Jiangsu Deyuan Pharmaceutical、 CTTQなどを掲載しており、売上の面では、世界の2大企業が2022年にほぼ000％のシェアを占めています。

本レポートでは、製品タイプ、用途、主要メーカー、主要地域、国別の糖尿病用経口薬市場の包括的な概要、市場シェア、成長機会などの情報を提供しています。

【市場細分化】

この調査では糖尿病用経口薬市場をセグメンテーションし、種類別 (ビグアナイド類、スルホニルウレア剤、メグリチニド類、ジペプチジルペプチダーゼ-4（DPP-4）阻害剤、SGLT2阻害剤、チアゾリジンジオン、α-グルコシダーゼ阻害剤、その他)、用途別 (病院、診療所、その他)、および地域別 (アジア太平洋、南北アメリカ、ヨーロッパ、および中東・アフリカ) の市場規模を予測しています。

・種類別区分：ビグアナイド類、スルホニルウレア剤、メグリチニド類、ジペプチジルペプチダーゼ-4（DPP-4）阻害剤、SGLT2阻害剤、チアゾリジンジオン、α-グルコシダーゼ阻害剤、その他

・用途別区分：病院、診療所、その他

・地域別区分
南北アメリカ（アメリカ、カナダ、メキシコ、ブラジル）
アジア太平洋（中国、日本、韓国、東南アジア、インド、オーストラリア）
ヨーロッパ（ドイツ、フランス、イギリス、イタリア、ロシア）
中東・アフリカ（エジプト、南アフリカ、イスラエル、トルコ、GCC諸国）

【本レポートで扱う主な質問】

・世界の糖尿病用経口薬市場の10年間の市場状況・展望は？
・世界および地域別に見た糖尿病用経口薬市場成長の要因は何か？
・糖尿病用経口薬の市場機会はエンドマーケットの規模によってどのように変化するのか？
・糖尿病用経口薬のタイプ別、用途別の内訳は？
・新型コロナウイルス感染症とロシア・ウクライナ戦争の影響は？

********* 目次 *********

レポートの範囲
・市場の紹介
・分析対象期間
・調査の目的
・調査手法
・調査プロセスおよびデータソース
・経済指標
・通貨

エグゼクティブサマリー
・世界市場の概要：糖尿病用経口薬の年間販売量2018-2029、地域別現状・将来分析
・糖尿病用経口薬の種類別セグメント：ビグアナイド類、スルホニルウレア剤、メグリチニド類、ジペプチジルペプチダーゼ-4（DPP-4）阻害剤、SGLT2阻害剤、チアゾリジンジオン、α-グルコシダーゼ阻害剤、その他
・糖尿病用経口薬の種類別販売量：2018-2023年の販売量、売上、市場シェア、販売価格
・糖尿病用経口薬の用途別セグメント：病院、診療所、その他
・糖尿病用経口薬の用途別販売量：2018-2023年の販売量、売上、市場シェア、販売価格

企業別世界の糖尿病用経口薬市場
・企業別のグローバル糖尿病用経口薬市場データ：2018-2023年の年間販売量、市場シェア
・企業別の糖尿病用経口薬の年間売上：2018-2023年の売上、市場シェア
・企業別の糖尿病用経口薬販売価格
・主要企業の糖尿病用経口薬生産地域、販売地域、製品タイプ
・市場集中度分析
・新製品および潜在的な参加者
・合併と買収、拡大

糖尿病用経口薬の地域別レビュー
・地域別の糖尿病用経口薬市場規模2018-2023：年間販売量、売上
・主要国別の糖尿病用経口薬市場規模2018-2023：年間販売量、売上
・南北アメリカの糖尿病用経口薬販売の成長
・アジア太平洋の糖尿病用経口薬販売の成長
・ヨーロッパの糖尿病用経口薬販売の成長
・中東・アフリカの糖尿病用経口薬販売の成長

南北アメリカ市場
・南北アメリカの国別の糖尿病用経口薬販売量、売上（2018-2023）
・南北アメリカの糖尿病用経口薬の種類別販売量
・南北アメリカの糖尿病用経口薬の用途別販売量
・アメリカ市場
・カナダ市場
・メキシコ市場
・ブラジル市場

アジア太平洋市場
・アジア太平洋の国別の糖尿病用経口薬販売量、売上（2018-2023）
・アジア太平洋の糖尿病用経口薬の種類別販売量
・アジア太平洋の糖尿病用経口薬の用途別販売量
・中国市場
・日本市場
・韓国市場
・東南アジア市場
・インド市場
・オーストラリア市場
・台湾市場

ヨーロッパ市場
・ヨーロッパの国別の糖尿病用経口薬販売量、売上（2018-2023）
・ヨーロッパの糖尿病用経口薬の種類別販売量
・ヨーロッパの糖尿病用経口薬の用途別販売量
・ドイツ市場
・フランス市場
・イギリス市場
・イタリア市場
・ロシア市場

中東・アフリカ市場
・中東・アフリカの国別の糖尿病用経口薬販売量、売上（2018-2023）
・中東・アフリカの糖尿病用経口薬の種類別販売量
・中東・アフリカの糖尿病用経口薬の用途別販売量
・エジプト市場
・南アフリカ市場
・イスラエル市場
・トルコ市場
・GCC諸国市場

市場の成長要因、課題、動向
・市場の成長要因および成長機会分析
・市場の課題およびリスク
・市場動向

製造コスト構造分析
・原材料とサプライヤー
・糖尿病用経口薬の製造コスト構造分析
・糖尿病用経口薬の製造プロセス分析
・糖尿病用経口薬の産業チェーン構造

マーケティング、販売業者および顧客
・販売チャンネル：直接販売チャンネル、間接販売チャンネル
・糖尿病用経口薬の主要なグローバル販売業者
・糖尿病用経口薬の主要なグローバル顧客

地域別の糖尿病用経口薬市場予測レビュー
・地域別の糖尿病用経口薬市場規模予測（2024-2029）
・南北アメリカの国別予測
・アジア太平洋の国別予測
・ヨーロッパの国別予測
・糖尿病用経口薬の種類別市場規模予測
・糖尿病用経口薬の用途別市場規模予測

主要企業分析
Bayer、 Merck、 Novartis、 Huadong Medicine、 Sanofi、 Novo Nordisk、 Servier、 Takeda Pharmaceutical、 Luye Pharmaceutical、 Taiji Group、 CR Double-Crane、 AstraZeneca、 Boehringer Ingelheim、 Qilu Pharmaceutical、 Jiangsu Deyuan Pharmaceutical、 CTTQ
・企業情報
・糖尿病用経口薬製品
・糖尿病用経口薬販売量、売上、価格、粗利益（2018-2023）
・主要ビジネス概要
・最新動向

調査結果および結論

The global Oral Medicines for Diabetes market size is projected to grow from US$ 59870 million in 2022 to US$ 124920 million in 2029; it is expected to grow at a CAGR of 11.1% from 2023 to 2029.
United States market for Oral Medicines for Diabetes is estimated to increase from US$ million in 2022 to US$ million by 2029, at a CAGR of % from 2023 through 2029.
China market for Oral Medicines for Diabetes is estimated to increase from US$ million in 2022 to US$ million by 2029, at a CAGR of % from 2023 through 2029.
Europe market for Oral Medicines for Diabetes is estimated to increase from US$ million in 2022 to US$ million by 2029, at a CAGR of % from 2023 through 2029.
Global key Oral Medicines for Diabetes players cover Bayer, Merck, Novartis, Huadong Medicine, Sanofi, Novo Nordisk, Servier, Takeda Pharmaceutical and Luye Pharmaceutical, etc. In terms of revenue, the global two largest companies occupied for a share nearly % in 2022.
Oral medications for diabetes are medications that are taken by mouth to manage blood sugar levels in people with type 2 diabetes.
LPI (LP Information)’ newest research report, the “Oral Medicines for Diabetes Industry Forecast” looks at past sales and reviews total world Oral Medicines for Diabetes sales in 2022, providing a comprehensive analysis by region and market sector of projected Oral Medicines for Diabetes sales for 2023 through 2029. With Oral Medicines for Diabetes sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Oral Medicines for Diabetes industry.
This Insight Report provides a comprehensive analysis of the global Oral Medicines for Diabetes landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyzes the strategies of leading global companies with a focus on Oral Medicines for Diabetes portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms’ unique position in an accelerating global Oral Medicines for Diabetes market.
This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Oral Medicines for Diabetes and breaks down the forecast by type, by application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Oral Medicines for Diabetes.
This report presents a comprehensive overview, market shares, and growth opportunities of Oral Medicines for Diabetes market by product type, application, key manufacturers and key regions and countries.
Market Segmentation:
Segmentation by type
Biguanides
Sulfonylureas
Meglitinides
Dipeptidyl Peptidase-4 (DPP-4) Inhibitors
SGLT2 Inhibitors
Thiazolidinediones
Alpha-Glucosidase Inhibitors
Other
Segmentation by application
Hospital
Clinic
Other
This report also splits the market by region:
Americas
United States
Canada
Mexico
Brazil
APAC
China
Japan
Korea
Southeast Asia
India
Australia
Europe
Germany
France
UK
Italy
Russia
Middle East & Africa
Egypt
South Africa
Israel
Turkey
GCC Countries
The below companies that are profiled have been selected based on inputs gathered from primary experts and analyzing the company’s coverage, product portfolio, its market penetration.
Bayer
Merck
Novartis
Huadong Medicine
Sanofi
Novo Nordisk
Servier
Takeda Pharmaceutical
Luye Pharmaceutical
Taiji Group
CR Double-Crane
AstraZeneca
Boehringer Ingelheim
Qilu Pharmaceutical
Jiangsu Deyuan Pharmaceutical
CTTQ
Key Questions Addressed in this Report
What is the 10-year outlook for the global Oral Medicines for Diabetes market?
What factors are driving Oral Medicines for Diabetes market growth, globally and by region?
Which technologies are poised for the fastest growth by market and region?
How do Oral Medicines for Diabetes market opportunities vary by end market size?
How does Oral Medicines for Diabetes break out type, application?
What are the influences of COVID-19 and Russia-Ukraine war?

❖ レポートの目次 ❖

1 Scope of the Report
1.1 Market Introduction
1.2 Years Considered
1.3 Research Objectives
1.4 Market Research Methodology
1.5 Research Process and Data Source
1.6 Economic Indicators
1.7 Currency Considered
1.8 Market Estimation Caveats
2 Executive Summary
2.1 World Market Overview
2.1.1 Global Oral Medicines for Diabetes Annual Sales 2018-2029
2.1.2 World Current & Future Analysis for Oral Medicines for Diabetes by Geographic Region, 2018, 2022 & 2029
2.1.3 World Current & Future Analysis for Oral Medicines for Diabetes by Country/Region, 2018, 2022 & 2029
2.2 Oral Medicines for Diabetes Segment by Type
2.2.1 Biguanides
2.2.2 Sulfonylureas
2.2.3 Meglitinides
2.2.4 Dipeptidyl Peptidase-4 (DPP-4) Inhibitors
2.2.5 SGLT2 Inhibitors
2.2.6 Thiazolidinediones
2.2.7 Alpha-Glucosidase Inhibitors
2.2.8 Other
2.3 Oral Medicines for Diabetes Sales by Type
2.3.1 Global Oral Medicines for Diabetes Sales Market Share by Type (2018-2023)
2.3.2 Global Oral Medicines for Diabetes Revenue and Market Share by Type (2018-2023)
2.3.3 Global Oral Medicines for Diabetes Sale Price by Type (2018-2023)
2.4 Oral Medicines for Diabetes Segment by Application
2.4.1 Hospital
2.4.2 Clinic
2.4.3 Other
2.5 Oral Medicines for Diabetes Sales by Application
2.5.1 Global Oral Medicines for Diabetes Sale Market Share by Application (2018-2023)
2.5.2 Global Oral Medicines for Diabetes Revenue and Market Share by Application (2018-2023)
2.5.3 Global Oral Medicines for Diabetes Sale Price by Application (2018-2023)
3 Global Oral Medicines for Diabetes by Company
3.1 Global Oral Medicines for Diabetes Breakdown Data by Company
3.1.1 Global Oral Medicines for Diabetes Annual Sales by Company (2018-2023)
3.1.2 Global Oral Medicines for Diabetes Sales Market Share by Company (2018-2023)
3.2 Global Oral Medicines for Diabetes Annual Revenue by Company (2018-2023)
3.2.1 Global Oral Medicines for Diabetes Revenue by Company (2018-2023)
3.2.2 Global Oral Medicines for Diabetes Revenue Market Share by Company (2018-2023)
3.3 Global Oral Medicines for Diabetes Sale Price by Company
3.4 Key Manufacturers Oral Medicines for Diabetes Producing Area Distribution, Sales Area, Product Type
3.4.1 Key Manufacturers Oral Medicines for Diabetes Product Location Distribution
3.4.2 Players Oral Medicines for Diabetes Products Offered
3.5 Market Concentration Rate Analysis
3.5.1 Competition Landscape Analysis
3.5.2 Concentration Ratio (CR3, CR5 and CR10) & (2018-2023)
3.6 New Products and Potential Entrants
3.7 Mergers & Acquisitions, Expansion
4 World Historic Review for Oral Medicines for Diabetes by Geographic Region
4.1 World Historic Oral Medicines for Diabetes Market Size by Geographic Region (2018-2023)
4.1.1 Global Oral Medicines for Diabetes Annual Sales by Geographic Region (2018-2023)
4.1.2 Global Oral Medicines for Diabetes Annual Revenue by Geographic Region (2018-2023)
4.2 World Historic Oral Medicines for Diabetes Market Size by Country/Region (2018-2023)
4.2.1 Global Oral Medicines for Diabetes Annual Sales by Country/Region (2018-2023)
4.2.2 Global Oral Medicines for Diabetes Annual Revenue by Country/Region (2018-2023)
4.3 Americas Oral Medicines for Diabetes Sales Growth
4.4 APAC Oral Medicines for Diabetes Sales Growth
4.5 Europe Oral Medicines for Diabetes Sales Growth
4.6 Middle East & Africa Oral Medicines for Diabetes Sales Growth
5 Americas
5.1 Americas Oral Medicines for Diabetes Sales by Country
5.1.1 Americas Oral Medicines for Diabetes Sales by Country (2018-2023)
5.1.2 Americas Oral Medicines for Diabetes Revenue by Country (2018-2023)
5.2 Americas Oral Medicines for Diabetes Sales by Type
5.3 Americas Oral Medicines for Diabetes Sales by Application
5.4 United States
5.5 Canada
5.6 Mexico
5.7 Brazil
6 APAC
6.1 APAC Oral Medicines for Diabetes Sales by Region
6.1.1 APAC Oral Medicines for Diabetes Sales by Region (2018-2023)
6.1.2 APAC Oral Medicines for Diabetes Revenue by Region (2018-2023)
6.2 APAC Oral Medicines for Diabetes Sales by Type
6.3 APAC Oral Medicines for Diabetes Sales by Application
6.4 China
6.5 Japan
6.6 South Korea
6.7 Southeast Asia
6.8 India
6.9 Australia
6.10 China Taiwan
7 Europe
7.1 Europe Oral Medicines for Diabetes by Country
7.1.1 Europe Oral Medicines for Diabetes Sales by Country (2018-2023)
7.1.2 Europe Oral Medicines for Diabetes Revenue by Country (2018-2023)
7.2 Europe Oral Medicines for Diabetes Sales by Type
7.3 Europe Oral Medicines for Diabetes Sales by Application
7.4 Germany
7.5 France
7.6 UK
7.7 Italy
7.8 Russia
8 Middle East & Africa
8.1 Middle East & Africa Oral Medicines for Diabetes by Country
8.1.1 Middle East & Africa Oral Medicines for Diabetes Sales by Country (2018-2023)
8.1.2 Middle East & Africa Oral Medicines for Diabetes Revenue by Country (2018-2023)
8.2 Middle East & Africa Oral Medicines for Diabetes Sales by Type
8.3 Middle East & Africa Oral Medicines for Diabetes Sales by Application
8.4 Egypt
8.5 South Africa
8.6 Israel
8.7 Turkey
8.8 GCC Countries
9 Market Drivers, Challenges and Trends
9.1 Market Drivers & Growth Opportunities
9.2 Market Challenges & Risks
9.3 Industry Trends
10 Manufacturing Cost Structure Analysis
10.1 Raw Material and Suppliers
10.2 Manufacturing Cost Structure Analysis of Oral Medicines for Diabetes
10.3 Manufacturing Process Analysis of Oral Medicines for Diabetes
10.4 Industry Chain Structure of Oral Medicines for Diabetes
11 Marketing, Distributors and Customer
11.1 Sales Channel
11.1.1 Direct Channels
11.1.2 Indirect Channels
11.2 Oral Medicines for Diabetes Distributors
11.3 Oral Medicines for Diabetes Customer
12 World Forecast Review for Oral Medicines for Diabetes by Geographic Region
12.1 Global Oral Medicines for Diabetes Market Size Forecast by Region
12.1.1 Global Oral Medicines for Diabetes Forecast by Region (2024-2029)
12.1.2 Global Oral Medicines for Diabetes Annual Revenue Forecast by Region (2024-2029)
12.2 Americas Forecast by Country
12.3 APAC Forecast by Region
12.4 Europe Forecast by Country
12.5 Middle East & Africa Forecast by Country
12.6 Global Oral Medicines for Diabetes Forecast by Type
12.7 Global Oral Medicines for Diabetes Forecast by Application
13 Key Players Analysis
13.1 Bayer
13.1.1 Bayer Company Information
13.1.2 Bayer Oral Medicines for Diabetes Product Portfolios and Specifications
13.1.3 Bayer Oral Medicines for Diabetes Sales, Revenue, Price and Gross Margin (2018-2023)
13.1.4 Bayer Main Business Overview
13.1.5 Bayer Latest Developments
13.2 Merck
13.2.1 Merck Company Information
13.2.2 Merck Oral Medicines for Diabetes Product Portfolios and Specifications
13.2.3 Merck Oral Medicines for Diabetes Sales, Revenue, Price and Gross Margin (2018-2023)
13.2.4 Merck Main Business Overview
13.2.5 Merck Latest Developments
13.3 Novartis
13.3.1 Novartis Company Information
13.3.2 Novartis Oral Medicines for Diabetes Product Portfolios and Specifications
13.3.3 Novartis Oral Medicines for Diabetes Sales, Revenue, Price and Gross Margin (2018-2023)
13.3.4 Novartis Main Business Overview
13.3.5 Novartis Latest Developments
13.4 Huadong Medicine
13.4.1 Huadong Medicine Company Information
13.4.2 Huadong Medicine Oral Medicines for Diabetes Product Portfolios and Specifications
13.4.3 Huadong Medicine Oral Medicines for Diabetes Sales, Revenue, Price and Gross Margin (2018-2023)
13.4.4 Huadong Medicine Main Business Overview
13.4.5 Huadong Medicine Latest Developments
13.5 Sanofi
13.5.1 Sanofi Company Information
13.5.2 Sanofi Oral Medicines for Diabetes Product Portfolios and Specifications
13.5.3 Sanofi Oral Medicines for Diabetes Sales, Revenue, Price and Gross Margin (2018-2023)
13.5.4 Sanofi Main Business Overview
13.5.5 Sanofi Latest Developments
13.6 Novo Nordisk
13.6.1 Novo Nordisk Company Information
13.6.2 Novo Nordisk Oral Medicines for Diabetes Product Portfolios and Specifications
13.6.3 Novo Nordisk Oral Medicines for Diabetes Sales, Revenue, Price and Gross Margin (2018-2023)
13.6.4 Novo Nordisk Main Business Overview
13.6.5 Novo Nordisk Latest Developments
13.7 Servier
13.7.1 Servier Company Information
13.7.2 Servier Oral Medicines for Diabetes Product Portfolios and Specifications
13.7.3 Servier Oral Medicines for Diabetes Sales, Revenue, Price and Gross Margin (2018-2023)
13.7.4 Servier Main Business Overview
13.7.5 Servier Latest Developments
13.8 Takeda Pharmaceutical
13.8.1 Takeda Pharmaceutical Company Information
13.8.2 Takeda Pharmaceutical Oral Medicines for Diabetes Product Portfolios and Specifications
13.8.3 Takeda Pharmaceutical Oral Medicines for Diabetes Sales, Revenue, Price and Gross Margin (2018-2023)
13.8.4 Takeda Pharmaceutical Main Business Overview
13.8.5 Takeda Pharmaceutical Latest Developments
13.9 Luye Pharmaceutical
13.9.1 Luye Pharmaceutical Company Information
13.9.2 Luye Pharmaceutical Oral Medicines for Diabetes Product Portfolios and Specifications
13.9.3 Luye Pharmaceutical Oral Medicines for Diabetes Sales, Revenue, Price and Gross Margin (2018-2023)
13.9.4 Luye Pharmaceutical Main Business Overview
13.9.5 Luye Pharmaceutical Latest Developments
13.10 Taiji Group
13.10.1 Taiji Group Company Information
13.10.2 Taiji Group Oral Medicines for Diabetes Product Portfolios and Specifications
13.10.3 Taiji Group Oral Medicines for Diabetes Sales, Revenue, Price and Gross Margin (2018-2023)
13.10.4 Taiji Group Main Business Overview
13.10.5 Taiji Group Latest Developments
13.11 CR Double-Crane
13.11.1 CR Double-Crane Company Information
13.11.2 CR Double-Crane Oral Medicines for Diabetes Product Portfolios and Specifications
13.11.3 CR Double-Crane Oral Medicines for Diabetes Sales, Revenue, Price and Gross Margin (2018-2023)
13.11.4 CR Double-Crane Main Business Overview
13.11.5 CR Double-Crane Latest Developments
13.12 AstraZeneca
13.12.1 AstraZeneca Company Information
13.12.2 AstraZeneca Oral Medicines for Diabetes Product Portfolios and Specifications
13.12.3 AstraZeneca Oral Medicines for Diabetes Sales, Revenue, Price and Gross Margin (2018-2023)
13.12.4 AstraZeneca Main Business Overview
13.12.5 AstraZeneca Latest Developments
13.13 Boehringer Ingelheim
13.13.1 Boehringer Ingelheim Company Information
13.13.2 Boehringer Ingelheim Oral Medicines for Diabetes Product Portfolios and Specifications
13.13.3 Boehringer Ingelheim Oral Medicines for Diabetes Sales, Revenue, Price and Gross Margin (2018-2023)
13.13.4 Boehringer Ingelheim Main Business Overview
13.13.5 Boehringer Ingelheim Latest Developments
13.14 Qilu Pharmaceutical
13.14.1 Qilu Pharmaceutical Company Information
13.14.2 Qilu Pharmaceutical Oral Medicines for Diabetes Product Portfolios and Specifications
13.14.3 Qilu Pharmaceutical Oral Medicines for Diabetes Sales, Revenue, Price and Gross Margin (2018-2023)
13.14.4 Qilu Pharmaceutical Main Business Overview
13.14.5 Qilu Pharmaceutical Latest Developments
13.15 Jiangsu Deyuan Pharmaceutical
13.15.1 Jiangsu Deyuan Pharmaceutical Company Information
13.15.2 Jiangsu Deyuan Pharmaceutical Oral Medicines for Diabetes Product Portfolios and Specifications
13.15.3 Jiangsu Deyuan Pharmaceutical Oral Medicines for Diabetes Sales, Revenue, Price and Gross Margin (2018-2023)
13.15.4 Jiangsu Deyuan Pharmaceutical Main Business Overview
13.15.5 Jiangsu Deyuan Pharmaceutical Latest Developments
13.16 CTTQ
13.16.1 CTTQ Company Information
13.16.2 CTTQ Oral Medicines for Diabetes Product Portfolios and Specifications
13.16.3 CTTQ Oral Medicines for Diabetes Sales, Revenue, Price and Gross Margin (2018-2023)
13.16.4 CTTQ Main Business Overview
13.16.5 CTTQ Latest Developments
14 Research Findings and Conclusion

List of Tables
Table 1. Oral Medicines for Diabetes Annual Sales CAGR by Geographic Region (2018, 2022 & 2029) & ($ millions)
Table 2. Oral Medicines for Diabetes Annual Sales CAGR by Country/Region (2018, 2022 & 2029) & ($ millions)
Table 3. Major Players of Biguanides
Table 4. Major Players of Sulfonylureas
Table 5. Major Players of Meglitinides
Table 6. Major Players of Dipeptidyl Peptidase-4 (DPP-4) Inhibitors
Table 7. Major Players of SGLT2 Inhibitors
Table 8. Major Players of Thiazolidinediones
Table 9. Major Players of Alpha-Glucosidase Inhibitors
Table 10. Major Players of Other
Table 11. Global Oral Medicines for Diabetes Sales by Type (2018-2023) & (K Units)
Table 12. Global Oral Medicines for Diabetes Sales Market Share by Type (2018-2023)
Table 13. Global Oral Medicines for Diabetes Revenue by Type (2018-2023) & ($ million)
Table 14. Global Oral Medicines for Diabetes Revenue Market Share by Type (2018-2023)
Table 15. Global Oral Medicines for Diabetes Sale Price by Type (2018-2023) & (US$/Unit)
Table 16. Global Oral Medicines for Diabetes Sales by Application (2018-2023) & (K Units)
Table 17. Global Oral Medicines for Diabetes Sales Market Share by Application (2018-2023)
Table 18. Global Oral Medicines for Diabetes Revenue by Application (2018-2023)
Table 19. Global Oral Medicines for Diabetes Revenue Market Share by Application (2018-2023)
Table 20. Global Oral Medicines for Diabetes Sale Price by Application (2018-2023) & (US$/Unit)
Table 21. Global Oral Medicines for Diabetes Sales by Company (2018-2023) & (K Units)
Table 22. Global Oral Medicines for Diabetes Sales Market Share by Company (2018-2023)
Table 23. Global Oral Medicines for Diabetes Revenue by Company (2018-2023) ($ Millions)
Table 24. Global Oral Medicines for Diabetes Revenue Market Share by Company (2018-2023)
Table 25. Global Oral Medicines for Diabetes Sale Price by Company (2018-2023) & (US$/Unit)
Table 26. Key Manufacturers Oral Medicines for Diabetes Producing Area Distribution and Sales Area
Table 27. Players Oral Medicines for Diabetes Products Offered
Table 28. Oral Medicines for Diabetes Concentration Ratio (CR3, CR5 and CR10) & (2018-2023)
Table 29. New Products and Potential Entrants
Table 30. Mergers & Acquisitions, Expansion
Table 31. Global Oral Medicines for Diabetes Sales by Geographic Region (2018-2023) & (K Units)
Table 32. Global Oral Medicines for Diabetes Sales Market Share Geographic Region (2018-2023)
Table 33. Global Oral Medicines for Diabetes Revenue by Geographic Region (2018-2023) & ($ millions)
Table 34. Global Oral Medicines for Diabetes Revenue Market Share by Geographic Region (2018-2023)
Table 35. Global Oral Medicines for Diabetes Sales by Country/Region (2018-2023) & (K Units)
Table 36. Global Oral Medicines for Diabetes Sales Market Share by Country/Region (2018-2023)
Table 37. Global Oral Medicines for Diabetes Revenue by Country/Region (2018-2023) & ($ millions)
Table 38. Global Oral Medicines for Diabetes Revenue Market Share by Country/Region (2018-2023)
Table 39. Americas Oral Medicines for Diabetes Sales by Country (2018-2023) & (K Units)
Table 40. Americas Oral Medicines for Diabetes Sales Market Share by Country (2018-2023)
Table 41. Americas Oral Medicines for Diabetes Revenue by Country (2018-2023) & ($ Millions)
Table 42. Americas Oral Medicines for Diabetes Revenue Market Share by Country (2018-2023)
Table 43. Americas Oral Medicines for Diabetes Sales by Type (2018-2023) & (K Units)
Table 44. Americas Oral Medicines for Diabetes Sales by Application (2018-2023) & (K Units)
Table 45. APAC Oral Medicines for Diabetes Sales by Region (2018-2023) & (K Units)
Table 46. APAC Oral Medicines for Diabetes Sales Market Share by Region (2018-2023)
Table 47. APAC Oral Medicines for Diabetes Revenue by Region (2018-2023) & ($ Millions)
Table 48. APAC Oral Medicines for Diabetes Revenue Market Share by Region (2018-2023)
Table 49. APAC Oral Medicines for Diabetes Sales by Type (2018-2023) & (K Units)
Table 50. APAC Oral Medicines for Diabetes Sales by Application (2018-2023) & (K Units)
Table 51. Europe Oral Medicines for Diabetes Sales by Country (2018-2023) & (K Units)
Table 52. Europe Oral Medicines for Diabetes Sales Market Share by Country (2018-2023)
Table 53. Europe Oral Medicines for Diabetes Revenue by Country (2018-2023) & ($ Millions)
Table 54. Europe Oral Medicines for Diabetes Revenue Market Share by Country (2018-2023)
Table 55. Europe Oral Medicines for Diabetes Sales by Type (2018-2023) & (K Units)
Table 56. Europe Oral Medicines for Diabetes Sales by Application (2018-2023) & (K Units)
Table 57. Middle East & Africa Oral Medicines for Diabetes Sales by Country (2018-2023) & (K Units)
Table 58. Middle East & Africa Oral Medicines for Diabetes Sales Market Share by Country (2018-2023)
Table 59. Middle East & Africa Oral Medicines for Diabetes Revenue by Country (2018-2023) & ($ Millions)
Table 60. Middle East & Africa Oral Medicines for Diabetes Revenue Market Share by Country (2018-2023)
Table 61. Middle East & Africa Oral Medicines for Diabetes Sales by Type (2018-2023) & (K Units)
Table 62. Middle East & Africa Oral Medicines for Diabetes Sales by Application (2018-2023) & (K Units)
Table 63. Key Market Drivers & Growth Opportunities of Oral Medicines for Diabetes
Table 64. Key Market Challenges & Risks of Oral Medicines for Diabetes
Table 65. Key Industry Trends of Oral Medicines for Diabetes
Table 66. Oral Medicines for Diabetes Raw Material
Table 67. Key Suppliers of Raw Materials
Table 68. Oral Medicines for Diabetes Distributors List
Table 69. Oral Medicines for Diabetes Customer List
Table 70. Global Oral Medicines for Diabetes Sales Forecast by Region (2024-2029) & (K Units)
Table 71. Global Oral Medicines for Diabetes Revenue Forecast by Region (2024-2029) & ($ millions)
Table 72. Americas Oral Medicines for Diabetes Sales Forecast by Country (2024-2029) & (K Units)
Table 73. Americas Oral Medicines for Diabetes Revenue Forecast by Country (2024-2029) & ($ millions)
Table 74. APAC Oral Medicines for Diabetes Sales Forecast by Region (2024-2029) & (K Units)
Table 75. APAC Oral Medicines for Diabetes Revenue Forecast by Region (2024-2029) & ($ millions)
Table 76. Europe Oral Medicines for Diabetes Sales Forecast by Country (2024-2029) & (K Units)
Table 77. Europe Oral Medicines for Diabetes Revenue Forecast by Country (2024-2029) & ($ millions)
Table 78. Middle East & Africa Oral Medicines for Diabetes Sales Forecast by Country (2024-2029) & (K Units)
Table 79. Middle East & Africa Oral Medicines for Diabetes Revenue Forecast by Country (2024-2029) & ($ millions)
Table 80. Global Oral Medicines for Diabetes Sales Forecast by Type (2024-2029) & (K Units)
Table 81. Global Oral Medicines for Diabetes Revenue Forecast by Type (2024-2029) & ($ Millions)
Table 82. Global Oral Medicines for Diabetes Sales Forecast by Application (2024-2029) & (K Units)
Table 83. Global Oral Medicines for Diabetes Revenue Forecast by Application (2024-2029) & ($ Millions)
Table 84. Bayer Basic Information, Oral Medicines for Diabetes Manufacturing Base, Sales Area and Its Competitors
Table 85. Bayer Oral Medicines for Diabetes Product Portfolios and Specifications
Table 86. Bayer Oral Medicines for Diabetes Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2018-2023)
Table 87. Bayer Main Business
Table 88. Bayer Latest Developments
Table 89. Merck Basic Information, Oral Medicines for Diabetes Manufacturing Base, Sales Area and Its Competitors
Table 90. Merck Oral Medicines for Diabetes Product Portfolios and Specifications
Table 91. Merck Oral Medicines for Diabetes Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2018-2023)
Table 92. Merck Main Business
Table 93. Merck Latest Developments
Table 94. Novartis Basic Information, Oral Medicines for Diabetes Manufacturing Base, Sales Area and Its Competitors
Table 95. Novartis Oral Medicines for Diabetes Product Portfolios and Specifications
Table 96. Novartis Oral Medicines for Diabetes Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2018-2023)
Table 97. Novartis Main Business
Table 98. Novartis Latest Developments
Table 99. Huadong Medicine Basic Information, Oral Medicines for Diabetes Manufacturing Base, Sales Area and Its Competitors
Table 100. Huadong Medicine Oral Medicines for Diabetes Product Portfolios and Specifications
Table 101. Huadong Medicine Oral Medicines for Diabetes Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2018-2023)
Table 102. Huadong Medicine Main Business
Table 103. Huadong Medicine Latest Developments
Table 104. Sanofi Basic Information, Oral Medicines for Diabetes Manufacturing Base, Sales Area and Its Competitors
Table 105. Sanofi Oral Medicines for Diabetes Product Portfolios and Specifications
Table 106. Sanofi Oral Medicines for Diabetes Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2018-2023)
Table 107. Sanofi Main Business
Table 108. Sanofi Latest Developments
Table 109. Novo Nordisk Basic Information, Oral Medicines for Diabetes Manufacturing Base, Sales Area and Its Competitors
Table 110. Novo Nordisk Oral Medicines for Diabetes Product Portfolios and Specifications
Table 111. Novo Nordisk Oral Medicines for Diabetes Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2018-2023)
Table 112. Novo Nordisk Main Business
Table 113. Novo Nordisk Latest Developments
Table 114. Servier Basic Information, Oral Medicines for Diabetes Manufacturing Base, Sales Area and Its Competitors
Table 115. Servier Oral Medicines for Diabetes Product Portfolios and Specifications
Table 116. Servier Oral Medicines for Diabetes Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2018-2023)
Table 117. Servier Main Business
Table 118. Servier Latest Developments
Table 119. Takeda Pharmaceutical Basic Information, Oral Medicines for Diabetes Manufacturing Base, Sales Area and Its Competitors
Table 120. Takeda Pharmaceutical Oral Medicines for Diabetes Product Portfolios and Specifications
Table 121. Takeda Pharmaceutical Oral Medicines for Diabetes Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2018-2023)
Table 122. Takeda Pharmaceutical Main Business
Table 123. Takeda Pharmaceutical Latest Developments
Table 124. Luye Pharmaceutical Basic Information, Oral Medicines for Diabetes Manufacturing Base, Sales Area and Its Competitors
Table 125. Luye Pharmaceutical Oral Medicines for Diabetes Product Portfolios and Specifications
Table 126. Luye Pharmaceutical Oral Medicines for Diabetes Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2018-2023)
Table 127. Luye Pharmaceutical Main Business
Table 128. Luye Pharmaceutical Latest Developments
Table 129. Taiji Group Basic Information, Oral Medicines for Diabetes Manufacturing Base, Sales Area and Its Competitors
Table 130. Taiji Group Oral Medicines for Diabetes Product Portfolios and Specifications
Table 131. Taiji Group Oral Medicines for Diabetes Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2018-2023)
Table 132. Taiji Group Main Business
Table 133. Taiji Group Latest Developments
Table 134. CR Double-Crane Basic Information, Oral Medicines for Diabetes Manufacturing Base, Sales Area and Its Competitors
Table 135. CR Double-Crane Oral Medicines for Diabetes Product Portfolios and Specifications
Table 136. CR Double-Crane Oral Medicines for Diabetes Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2018-2023)
Table 137. CR Double-Crane Main Business
Table 138. CR Double-Crane Latest Developments
Table 139. AstraZeneca Basic Information, Oral Medicines for Diabetes Manufacturing Base, Sales Area and Its Competitors
Table 140. AstraZeneca Oral Medicines for Diabetes Product Portfolios and Specifications
Table 141. AstraZeneca Oral Medicines for Diabetes Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2018-2023)
Table 142. AstraZeneca Main Business
Table 143. AstraZeneca Latest Developments
Table 144. Boehringer Ingelheim Basic Information, Oral Medicines for Diabetes Manufacturing Base, Sales Area and Its Competitors
Table 145. Boehringer Ingelheim Oral Medicines for Diabetes Product Portfolios and Specifications
Table 146. Boehringer Ingelheim Oral Medicines for Diabetes Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2018-2023)
Table 147. Boehringer Ingelheim Main Business
Table 148. Boehringer Ingelheim Latest Developments
Table 149. Qilu Pharmaceutical Basic Information, Oral Medicines for Diabetes Manufacturing Base, Sales Area and Its Competitors
Table 150. Qilu Pharmaceutical Oral Medicines for Diabetes Product Portfolios and Specifications
Table 151. Qilu Pharmaceutical Oral Medicines for Diabetes Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2018-2023)
Table 152. Qilu Pharmaceutical Main Business
Table 153. Qilu Pharmaceutical Latest Developments
Table 154. Jiangsu Deyuan Pharmaceutical Basic Information, Oral Medicines for Diabetes Manufacturing Base, Sales Area and Its Competitors
Table 155. Jiangsu Deyuan Pharmaceutical Oral Medicines for Diabetes Product Portfolios and Specifications
Table 156. Jiangsu Deyuan Pharmaceutical Oral Medicines for Diabetes Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2018-2023)
Table 157. Jiangsu Deyuan Pharmaceutical Main Business
Table 158. Jiangsu Deyuan Pharmaceutical Latest Developments
Table 159. CTTQ Basic Information, Oral Medicines for Diabetes Manufacturing Base, Sales Area and Its Competitors
Table 160. CTTQ Oral Medicines for Diabetes Product Portfolios and Specifications
Table 161. CTTQ Oral Medicines for Diabetes Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2018-2023)
Table 162. CTTQ Main Business
Table 163. CTTQ Latest Developments
List of Figures
Figure 1. Picture of Oral Medicines for Diabetes
Figure 2. Oral Medicines for Diabetes Report Years Considered
Figure 3. Research Objectives
Figure 4. Research Methodology
Figure 5. Research Process and Data Source
Figure 6. Global Oral Medicines for Diabetes Sales Growth Rate 2018-2029 (K Units)
Figure 7. Global Oral Medicines for Diabetes Revenue Growth Rate 2018-2029 ($ Millions)
Figure 8. Oral Medicines for Diabetes Sales by Region (2018, 2022 & 2029) & ($ Millions)
Figure 9. Product Picture of Biguanides
Figure 10. Product Picture of Sulfonylureas
Figure 11. Product Picture of Meglitinides
Figure 12. Product Picture of Dipeptidyl Peptidase-4 (DPP-4) Inhibitors
Figure 13. Product Picture of SGLT2 Inhibitors
Figure 14. Product Picture of Thiazolidinediones
Figure 15. Product Picture of Alpha-Glucosidase Inhibitors
Figure 16. Product Picture of Other
Figure 17. Global Oral Medicines for Diabetes Sales Market Share by Type in 2022
Figure 18. Global Oral Medicines for Diabetes Revenue Market Share by Type (2018-2023)
Figure 19. Oral Medicines for Diabetes Consumed in Hospital
Figure 20. Global Oral Medicines for Diabetes Market: Hospital (2018-2023) & (K Units)
Figure 21. Oral Medicines for Diabetes Consumed in Clinic
Figure 22. Global Oral Medicines for Diabetes Market: Clinic (2018-2023) & (K Units)
Figure 23. Oral Medicines for Diabetes Consumed in Other
Figure 24. Global Oral Medicines for Diabetes Market: Other (2018-2023) & (K Units)
Figure 25. Global Oral Medicines for Diabetes Sales Market Share by Application (2022)
Figure 26. Global Oral Medicines for Diabetes Revenue Market Share by Application in 2022
Figure 27. Oral Medicines for Diabetes Sales Market by Company in 2022 (K Units)
Figure 28. Global Oral Medicines for Diabetes Sales Market Share by Company in 2022
Figure 29. Oral Medicines for Diabetes Revenue Market by Company in 2022 ($ Million)
Figure 30. Global Oral Medicines for Diabetes Revenue Market Share by Company in 2022
Figure 31. Global Oral Medicines for Diabetes Sales Market Share by Geographic Region (2018-2023)
Figure 32. Global Oral Medicines for Diabetes Revenue Market Share by Geographic Region in 2022
Figure 33. Americas Oral Medicines for Diabetes Sales 2018-2023 (K Units)
Figure 34. Americas Oral Medicines for Diabetes Revenue 2018-2023 ($ Millions)
Figure 35. APAC Oral Medicines for Diabetes Sales 2018-2023 (K Units)
Figure 36. APAC Oral Medicines for Diabetes Revenue 2018-2023 ($ Millions)
Figure 37. Europe Oral Medicines for Diabetes Sales 2018-2023 (K Units)
Figure 38. Europe Oral Medicines for Diabetes Revenue 2018-2023 ($ Millions)
Figure 39. Middle East & Africa Oral Medicines for Diabetes Sales 2018-2023 (K Units)
Figure 40. Middle East & Africa Oral Medicines for Diabetes Revenue 2018-2023 ($ Millions)
Figure 41. Americas Oral Medicines for Diabetes Sales Market Share by Country in 2022
Figure 42. Americas Oral Medicines for Diabetes Revenue Market Share by Country in 2022
Figure 43. Americas Oral Medicines for Diabetes Sales Market Share by Type (2018-2023)
Figure 44. Americas Oral Medicines for Diabetes Sales Market Share by Application (2018-2023)
Figure 45. United States Oral Medicines for Diabetes Revenue Growth 2018-2023 ($ Millions)
Figure 46. Canada Oral Medicines for Diabetes Revenue Growth 2018-2023 ($ Millions)
Figure 47. Mexico Oral Medicines for Diabetes Revenue Growth 2018-2023 ($ Millions)
Figure 48. Brazil Oral Medicines for Diabetes Revenue Growth 2018-2023 ($ Millions)
Figure 49. APAC Oral Medicines for Diabetes Sales Market Share by Region in 2022
Figure 50. APAC Oral Medicines for Diabetes Revenue Market Share by Regions in 2022
Figure 51. APAC Oral Medicines for Diabetes Sales Market Share by Type (2018-2023)
Figure 52. APAC Oral Medicines for Diabetes Sales Market Share by Application (2018-2023)
Figure 53. China Oral Medicines for Diabetes Revenue Growth 2018-2023 ($ Millions)
Figure 54. Japan Oral Medicines for Diabetes Revenue Growth 2018-2023 ($ Millions)
Figure 55. South Korea Oral Medicines for Diabetes Revenue Growth 2018-2023 ($ Millions)
Figure 56. Southeast Asia Oral Medicines for Diabetes Revenue Growth 2018-2023 ($ Millions)
Figure 57. India Oral Medicines for Diabetes Revenue Growth 2018-2023 ($ Millions)
Figure 58. Australia Oral Medicines for Diabetes Revenue Growth 2018-2023 ($ Millions)
Figure 59. China Taiwan Oral Medicines for Diabetes Revenue Growth 2018-2023 ($ Millions)
Figure 60. Europe Oral Medicines for Diabetes Sales Market Share by Country in 2022
Figure 61. Europe Oral Medicines for Diabetes Revenue Market Share by Country in 2022
Figure 62. Europe Oral Medicines for Diabetes Sales Market Share by Type (2018-2023)
Figure 63. Europe Oral Medicines for Diabetes Sales Market Share by Application (2018-2023)
Figure 64. Germany Oral Medicines for Diabetes Revenue Growth 2018-2023 ($ Millions)
Figure 65. France Oral Medicines for Diabetes Revenue Growth 2018-2023 ($ Millions)
Figure 66. UK Oral Medicines for Diabetes Revenue Growth 2018-2023 ($ Millions)
Figure 67. Italy Oral Medicines for Diabetes Revenue Growth 2018-2023 ($ Millions)
Figure 68. Russia Oral Medicines for Diabetes Revenue Growth 2018-2023 ($ Millions)
Figure 69. Middle East & Africa Oral Medicines for Diabetes Sales Market Share by Country in 2022
Figure 70. Middle East & Africa Oral Medicines for Diabetes Revenue Market Share by Country in 2022
Figure 71. Middle East & Africa Oral Medicines for Diabetes Sales Market Share by Type (2018-2023)
Figure 72. Middle East & Africa Oral Medicines for Diabetes Sales Market Share by Application (2018-2023)
Figure 73. Egypt Oral Medicines for Diabetes Revenue Growth 2018-2023 ($ Millions)
Figure 74. South Africa Oral Medicines for Diabetes Revenue Growth 2018-2023 ($ Millions)
Figure 75. Israel Oral Medicines for Diabetes Revenue Growth 2018-2023 ($ Millions)
Figure 76. Turkey Oral Medicines for Diabetes Revenue Growth 2018-2023 ($ Millions)
Figure 77. GCC Country Oral Medicines for Diabetes Revenue Growth 2018-2023 ($ Millions)
Figure 78. Manufacturing Cost Structure Analysis of Oral Medicines for Diabetes in 2022
Figure 79. Manufacturing Process Analysis of Oral Medicines for Diabetes
Figure 80. Industry Chain Structure of Oral Medicines for Diabetes
Figure 81. Channels of Distribution
Figure 82. Global Oral Medicines for Diabetes Sales Market Forecast by Region (2024-2029)
Figure 83. Global Oral Medicines for Diabetes Revenue Market Share Forecast by Region (2024-2029)
Figure 84. Global Oral Medicines for Diabetes Sales Market Share Forecast by Type (2024-2029)
Figure 85. Global Oral Medicines for Diabetes Revenue Market Share Forecast by Type (2024-2029)
Figure 86. Global Oral Medicines for Diabetes Sales Market Share Forecast by Application (2024-2029)
Figure 87. Global Oral Medicines for Diabetes Revenue Market Share Forecast by Application (2024-2029)


★調査レポート[世界の糖尿病用経口薬市場予測 2023年-2029年] (コード：LP23DC03882)販売に関する免責事項を必ずご確認ください。
★調査レポート[世界の糖尿病用経口薬市場予測 2023年-2029年]についてメールでお問い合わせ
◆関連市場調査レポート◆
  • 世界の5-フルオシトシン医薬品市場予測 2023年-2029年
  • 世界の5-フルオシトシン医薬品市場予測 2023年-2029年
  • 世界の副甲状腺及び関連医薬品市場予測 2023年-2029年
  • 世界の経口新型コロナウイルス感染症ワクチン市場予測 2023年-2029年
  • 世界の医薬品内服液用PETボトル市場予測 2023年-2029年

    • ◆H&Iグローバルリサーチのお客様（例）◆